Caricamento...

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

CONTEXT: The phosphoinositide 3-kinase (PI3K)/Akt pathway is widely postulated to be an effective therapeutic target in thyroid cancer. OBJECTIVE: The aim of the study was to test the therapeutic potential of the novel Akt inhibitor MK2206 for thyroid cancer. DESIGN: We examined the effects of MK220...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Liu, Ruixin, Liu, Dingxie, Trink, Eliana, Bojdani, Ermal, Ning, Guang, Xing, Mingzhao
Natura: Artigo
Lingua:Inglês
Pubblicazione: Endocrine Society 2011
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3070256/
https://ncbi.nlm.nih.gov/pubmed/21289267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2010-2644
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !